Search results
22 sty 2021 · Among patients with a distant recurrence, 37% had metastases in non-regional lymph nodes, 31% in the liver and 30% in the lung. After disease recurrence, 29% of patients received systemic therapy (chemo- or targeted therapy), 5% chemoradiotherapy, 1% surgery and 66% best supportive care only.
1 lis 2023 · Surgical treatments provided significantly better survival outcomes than CRT or chemo-/radiotherapy alone (3-year overall survival (OS); 78.1% vs. 42.5% vs. 28.9%, P < 0.01), mainly due to prolonging survival after the recurrence (3-year PRS 62.9% vs. 16.7% vs. 16.2%, P < 0.01).
1 lis 2023 · Abstract. Background. Little is known about predictive factors for survival outcomes of esophageal carcinoma (EC) patients who developed recurrence after undergoing multimodal therapies. We aimed to investigate long-term outcomes and identify prognostic factors in patients with relapsed EC, focusing especially on those with oligometastasis (OM).
3 cze 2023 · This study aimed to develop prediction models for long-term survival and time-to-recurrence following surgery for esophageal cancer using Cox proportional hazards (CPH) and random survival forest (RSF) and demonstrated good discrimination and calibration for both.
27 sty 2024 · The median time from definitive CRT to recurrence was 8.3 months. Treatment modalities included local therapy, systemic therapy, and palliative care. Overall survival (OS) after recurrence was analyzed using the Kaplan–Meier and Cox proportional hazards models.
Esophageal cancer is an aggressive malignancy with high rates of recurrence, even after completion of therapy with curative intent. Current National Comprehensive Cancer Network guidelines 2 recommend more-frequent follow-up, with medical history and physical examination, during the first 5 years.
30 mar 2024 · Pathological complete response is correlated with a favorable long-term survival. 6 Despite achieving a complete response after neoadjuvant chemoradiotherapy and surgery, 26% still develop a recurrence. Locoregional recurrence occurred in 17 of 61 (28%) patients.
